Compare ATOM & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATOM | MDWD |
|---|---|---|
| Founded | 2001 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.7M | 181.1M |
| IPO Year | 2016 | 2013 |
| Metric | ATOM | MDWD |
|---|---|---|
| Price | $4.28 | $13.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | ★ 404.0K | 104.0K |
| Earning Date | 05-05-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.41 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $62,000.00 | N/A |
| Revenue This Year | $527.69 | $48.92 |
| Revenue Next Year | N/A | $35.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.89 | $12.52 |
| 52 Week High | $12.37 | $20.03 |
| Indicator | ATOM | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 46.93 | 55.86 |
| Support Level | $4.19 | $13.80 |
| Resistance Level | $5.06 | $14.07 |
| Average True Range (ATR) | 0.20 | 0.53 |
| MACD | 0.10 | 0.09 |
| Stochastic Oscillator | 75.34 | 88.39 |
Atomera Inc is engaged in the business of developing, commercializing, and licensing proprietary processes and technologies for the semiconductor industry. The company's technology, named Mears Silicon Technology, or MST, is a thin film of re-engineered silicon, typically 100 to 300 angstroms (or approximately 20 to 60 silicon atomic unit cells) thick. MST can be applied as a transistor channel enhancement to CMOS-type transistors, the majority of widely used in the semiconductor industry. The company's silicon technology can be used for applications like Analog, DRAM, logic, processors, and SRAM. Geographically, it generates maximum revenue from North America.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.